Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors
A substantial obstacle in basic research is the use of poorly validated tool compounds with purported useful biological functions. Here, the authors systematically profile widely used histone acetyltransferase inhibitors and find that the majority are nonselective interference compounds.
Guardado en:
Autores principales: | Jayme L. Dahlin, Kathryn M. Nelson, Jessica M. Strasser, Dalia Barsyte-Lovejoy, Magdalena M. Szewczyk, Shawna Organ, Matthew Cuellar, Gurpreet Singh, Jonathan H. Shrimp, Nghi Nguyen, Jordan L. Meier, Cheryl H. Arrowsmith, Peter J. Brown, Jonathan B. Baell, Michael A. Walters |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8ca9ff19d5524b75acdb413bf0ff0f30 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
- Products Liability
-
Risk management of contingent liabilities within a sovereign asset-liability framework
por: Currie, Elizabeth, et al.
Publicado: (2014) -
Journal of products and toxics liability
Publicado: (1993) - Professional Liability Litigation @lert
- Professional Services Liability Litigation